# Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

> **NCT00432094** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 23 (actual)

## Conditions studied

- Childhood Germ Cell Tumor
- Ovarian Cancer
- Teratoma

## Interventions

- **DRUG:** carboplatin
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **DRUG:** paclitaxel
- **DRUG:** thiotepa
- **PROCEDURE:** autologous hematopoietic stem cell transplantation
- **DRUG:** Mesna
- **BIOLOGICAL:** filgrastim

## Key facts

- **NCT ID:** NCT00432094
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-19
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432094, "Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00432094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*